Eliska Furlong

Eliska Furlong

Auto-generated profile, based on publicly available information

Eliska Furlong

Leukaemia Translational Research Laboratory, WA Kids Cancer Centre, The Kids Research Institute Australia, Perth, WA, Australia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2020 in Journal of Paediatrics and Child Health
Verified
Journal Article
Closed access
PDF file
EFEliska Furlong
Eliska Furlong
TCTina Carter
Tina Carter

27 June 2024 in Blood Advances
Verified
Journal Article
Open access
PVParvathy Venugopal
Parvathy Venugopal
PAPeer Arts
Peer Arts
LFLucy Fox
Lucy Fox
ASAnnet Simons
Annet Simons
DHDevendra K. Hiwase
Devendra K. Hiwase
HSHamish S Scott
Hamish S Scott

20 October 2019 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
EFEliska Furlong
Eliska Furlong
JJJesper Jensen
Jesper Jensen
MWMark Woodard
Mark Woodard
KGKatherine Griffiths
Katherine Griffiths
GKGeoff Knight
Geoff Knight
SRShanti Ramachandran
Shanti Ramachandran

10 March 2022 in Medical Journal of Australia
Verified
Journal Article
Open access
PDF file
EFEliska Furlong
Eliska Furlong
RKRishi S Kotecha
Rishi S Kotecha
RCRachel Conyers
Rachel Conyers
TOTracey A O'Brien
Tracey A O'Brien
JHJordan R Hansford
Jordan R Hansford
LDLuciano Dalla-Pozza
Luciano Dalla-Pozza
Introduction The Australian Technical Advisory Group on Immunisation and New Zealand Ministry of Health recommend all children aged ≥ 5 years receive either of the two mRNA COVID-19 vaccines: Comirnaty (Pfizer), available in both Australia and New Zealand, or Spikevax (Moderna), available in Australia only. Both vaccines are efficacious and safe in the general population, including children. Children and adolescents undergoing treatment for cancer and immunosuppressive therapy for non-malignant haematological conditions are particularly vulnerable, with an increased risk of severe or fatal COVID-19. There remains a paucity of data regarding the immune response to COVID-19 vaccines in immunosuppressed paediatric populations, with data suggestive of reduced immunogenicity of the vaccine in immunocompromised adults. Recommendations Considering the safety profile of mRNA COVID-19 vaccines and the increased risk of severe COVID-19 in immunocompromised children and adolescents, COVID-19 vaccination is strongly recommended for this at-risk population. We provide a number of recommendations regarding COVID-19 vaccination in this population where immunosuppressive, chemotherapeutic and/or targeted biological agents are used. These include the timing of vaccination in patients undergoing active treatment, management of specific situations where vaccination is contraindicated or recommended under special precautions, and additional vaccination recommendations for severely immunocompromised patients. Finally, we stress the importance of upcoming clinical trials to identify the safest and most efficacious vaccination regimen for this population. Changes in management as a result of this statement This consensus statement provides recommendations for COVID-19 vaccination in children and adolescents aged ≥ 5 years with cancer and immunocompromising non-malignant haematological conditions, based on evidence, national and international guidelines and expert opinion.

1 April 2026 in Blood Advances
Verified
Journal Article
Open access
SCSung K Chiu
Sung K Chiu
EFEliska Furlong
Eliska Furlong
AFAnnette Fox
Annette Fox
EMElizabeth J. McKinnon
Elizabeth J. McKinnon
SOStephany Sánchez Ovando
Stephany Sánchez Ovando
RKRishi S Kotecha
Rishi S Kotecha